
    <html>
    <head><title>BABY.TO</title>
<style>
body {
  font-family: Arial, sans-serif;
  margin: 20px;
}
.container {
  display: grid;
  grid-template-columns: 50% 50%;
  grid-template-rows: auto auto;
  gap: 20px;
}
img {
  width: 100%;
  height: auto;
  max-height: 400px;
  border: 1px solid #ccc;
  object-fit: contain;
}

.cell {
  padding: 10px;
}
.table-scroll {
  max-height: 400px;
  overflow-y: auto;
  border: 1px solid #aaa;
}
table {
  width: 100%;
  border-collapse: collapse;
}
th, td {
  border: 1px solid #aaa;
  padding: 5px;
  text-align: left;
  font-size: 14px;
}
.negative {
  background: linear-gradient(to right, #ffdddd, white);
}
.positive {
  background: linear-gradient(to right, white, #ddffdd);
}
.pos-light  { background: #e6ffe6; }  
.pos-mid    { background: #99ff99; }  
.pos-strong { background: #33cc33; }   

.neg-light  { background: #ffe6e6; }   
.neg-mid    { background: #ff9999; }   
.neg-strong { background: #ff3333; }   

h2 { border-bottom: 2px solid #444; }
<script>
function toggleText(id) {
  const moreText = document.getElementById(id);
  const btn = document.getElementById(id + "_btn");

  if (moreText.style.display === "none") {
    moreText.style.display = "inline";
    btn.innerText = " Show less";
  } else {
    moreText.style.display = "none";
    btn.innerText = " Show more";
  }
}
</script>
</style>
</head>
    <body>
    <h2><span style='color:#1e66f5; font-weight:900; margin-right:10px;'>quarterly earnings d</span> BABY.TO  <span style='color:orange; font-weight:800; margin-left:8px;'>nan</span>
        <span style='font-weight:normal; font-size: 18px;'>(1502d - Product launches)</span>
        <span style='color:black; font-weight:bold; font-size: 20px;'> </span>
        <a href='https://finance.yahoo.com/chart/BABY.TO?interval=1mo' target='_blank'>Yahoo</a>
        <span style='font-weight:600;'>  — </span>
    </h2>

    <div class="container">
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><div class='table-scroll'><table><tr><th>Date</th><th>Score</th><th>AMR</th><th>Type</th><th>Summary</th><th>Links</th></tr><tr class='pos-light'><td>2025-11-18</td><td>0.35</td><td></td><td>FDA or Canada Health decisions</td><td>0.35 local feel              __   BABY.TO __    -> i:0.35<-                      <br><br>FEELING: total score +0.35 Breakdown: FDA or Canada Health decisions: +0.4 (The streamlining of FDA pathways for plant-based infant formulas is a major positive. This directly impacts Else Nutrition's ability to expand in the US market.) Product launches: +0.2 (The company's toddler nutrition line is strategically positioned, implying a potential for future product launches and growth.) Regulatory changes: +0.1 (Beneficial regulatory change for the industry) Negative Considerations (minimal impact): The news mentions monitoring FDA engagement and regulatory progress, which introduces a degree of uncertainty, but the overall sentiment remains positive. Note: Analyst ratings and backward-looking data are ignored as per instructions. --- <br> - This is a significant positive development for Else Nutrition. The FDA streamlining regulatory pathways for plant-based infant formulas, spurred by the budget agreement, removes a major hurdle for the company and opens up considerable growth potential in the US market. Investors should monitor FDA engagement and regulatory progress. <br><br>*** REZUMAT *** - FDA to streamline approval pathways for plant-based, non-soy, non-dairy infant formulas. - President Trump signed the U.S. Government budget for Fiscal Year 2026. - The budget ends the U.S. Government shutdown. - Operation Stork Speed initiative may now include plant-based formulas. - Else Nutrition expects engagement with FDA to begin soon. - Company's toddler nutrition line (almonds, buckwheat, tapioca) is strategically positioned. - The move addresses families with allergies, intolerances, or lifestyle preferences. - Else Nutrition will continue engagement with FDA and federal representatives. - Company is TSX: BABY, OTCQX: BABYF, FSE: 0YL.   (gemma3:12b-it-q4_K_M on 2025-11-18 21:47:31)</td><td><a href='https://www.prnewswire.com/news-releases/else-nutrition-announces-major-breakthrough-president-trump-signs-pivotal-fda-funding-package-that-includes-congressional-directive-streamlining-regulatory-pathway-for-non-dairy-non-soy-plant-based-infant-formula-302617738.html' target='_blank'>Link</a></td></tr><tr class='pos-mid'><td>2025-11-18</td><td>0.40</td><td></td><td>FDA decision</td><td>0.4 local feel              __   BABY.TO __    -> i:0.4<-                      <br><br>FEELING: total score +0.4 Reasoning: The news primarily revolves around a significant regulatory shift – a directive within the U.S. government budget to expedite FDA approval for plant-based infant formulas, specifically benefiting Else Nutrition. This falls under the "FDA or Canada Health decisions" event. FDA approval pathway boost: +0.4 - This is the most significant factor. The directive to expedite FDA approval represents a major positive catalyst for Else, potentially accelerating their market entry and growth in the U.S. The language used ("expedite," "accelerated growth," "regulatory paradigm shift") indicates a substantial positive impact. The potential inclusion in "Operation Stork Speed" further strengthens this. Other factors are minor and don't significantly alter the overall score: Government Affairs initiatives: Very low impact. Report Language directing FDA: Reinforces the main point, but doesn't add significant value. Toddler nutrition line suitability: Mildly positive, but secondary to the FDA approval pathway. The score reflects the potential for accelerated growth and market access due to this regulatory change. --- <br> - Else Nutrition receives a significant boost with the U.S. government budget signing, which includes a directive to expedite FDA approval for plant-based infant formulas. This represents a major regulatory shift and positions Else for accelerated growth in the U.S. market. Investors should monitor FDA engagement. <br><br>*** REZUMAT *** - Else Nutrition receives FDA pathway boost via U.S. budget signed by President Trump. - Budget ends government shutdown & expedites FDA approval for plant-based infant formula. - Directive secured through Company's Government Affairs initiatives. - FDA to streamline pathways for non-soy, non-dairy infant formula. - Operation Stork Speed initiative may now include plant-based formulas. - Else positioned to accelerate engagement with federal regulators. - Report Language directs FDA to establish clear approval pathways. - Else's toddler nutrition line (almonds, buckwheat, tapioca) is strategically suited. - Legislation signals a regulatory paradigm shift favoring innovation and choice. - Else will continue engagement with FDA and federal representatives.   (gemma3:12b-it-q4_K_M on 2025-11-18 21:49:57)</td><td><a href='https://www.stocktitan.net/news/BABYF/else-nutrition-announces-major-breakthrough-president-trump-signs-jcu0e6nfwraf.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-11-14</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.3 local feel              __   BABY.TO __    -> i:0.5<-                     **   ** 2025-11-17 **   <br><br>** 2025-11-17  quarterly earnings ***<br>FEELING: total score +0.3 Reasoning: quarterly or annual results: The news highlights a significant turnaround in Q3 2025 with a substantial improvement in gross margin (34% vs -9%) and a large reduction in operating expenses (68%). This strongly suggests results are above expectations, earning a +0.3. regulatory developments: The mention of "regulatory milestones" suggests potential future positive developments, adding a slight positive influence. backward-looking data: The comparison to Q3 2024 is relevant for context but doesn't drive the score significantly. cash position: The low cash position ($91K) is a negative, but the overall positive results outweigh this. revenue dip: The slight revenue dip is a minor negative, but the cost-control measures are more impactful. The overall sentiment is positive due to the significant improvements in margins and cost control, suggesting a potential for future profitability and growth. --- <br> - Else Nutrition's Q3 2025 results show a significant turnaround with a 34% gross margin and a 68% reduction in operating expenses. While revenue dipped slightly due to temporary stock issues, the company's cost-control initiatives and strategic focus position it for potential profitability and growth. Investors should monitor Q4 performance and regulatory developments. <br><br>*** REZUMAT *** - Q3 2025: Gross margin surged to 34% (vs -9% in Q3 2024). - Operating expenses down 68% YoY, to $1.15M (vs $3.56M in Q3 2024). - Operating loss reduced to $0.58M (vs $3.72M in Q3 2024). - Revenue stable at $1.66M, slightly down from $1.79M in Q3 2024. - Cash position at quarter-end: $91K. - Trade payables reduced by 46% to $1.53M. - Conference call scheduled for November 2025 at 10:00 AM ET. - Focus on resolving supply chain challenges and regulatory milestones.   (gemma3:12b-it-q4_K_M on 2025-11-14 22:16:35)</td><td><a href='https://www.stocktitan.net/news/BABYF/else-nutrition-reports-significant-operational-turnaround-in-q3-2025-ijc91fld2g4q.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-11-14</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.3 local feel              __   BABY.TO __    -> i:0.5<-                     **   ** 2025-11-17 **   <br><br>** 2025-11-17  quarterly earnings ***<br>FEELING: total score 0.3 Reasoning: Gross Margin Improvement (34% vs. -9%): This is a significant positive development. It suggests improved efficiency and pricing power. Score: +0.3 Operating Expenses Reduction (68% YoY): This indicates effective cost management. Score: +0.1 Revenue Dip: While a slight revenue decrease is negative, the focus on cost-cutting and margin improvement mitigates the impact. Score: -0.1 Regulatory Developments (U.S. infant formula standards): The mention of modernization is a mildly positive signal for future growth. Score: +0.1 Cash Position & Trade Payables: The low cash position ($91K) and significant trade payables ($1.53 million) are concerning and offset some of the positive news. Score: -0.1 Conference Call: A standard event, minimal impact. Score: 0 Summing the scores: 0.3 + 0.1 - 0.1 - 0.1 + 0 = 0.3 --- <br> - Else Nutrition demonstrates a significant operational turnaround with a dramatic improvement in gross margin (34%) and a 68% reduction in operating expenses. While revenue dipped slightly, the company's cost-cutting measures and strategic initiatives position it for potential profitability and recovery. Investors should monitor Q4 results and regulatory developments. <br><br>*** REZUMAT *** - Revenue: $1.66 million in Q3 2025, down from $1.79 million in Q3 2024. - Gross Profit Margin: Surged to 34% vs. -9% in Q3 2024. - Operating Expenses: Decreased by 68% YoY, to $1.15 million. - Operating Loss: Reduced to $0.58 million vs. $3.72 million in Q3 2024. - Cash Position: $91K at quarter-end. - Trade Payables: Reduced by 46% to $1.53 million. - Conference Call: November 17 at 10:00 AM Eastern Time. - Regulatory: Encouraged by modernization of U.S. infant formula standards.   (gemma3:12b-it-q4_K_M on 2025-11-14 22:17:44)</td><td><a href='https://investingnews.com/else-nutrition-reports-significant-operational-turnaround-in-q3-2025-with-gross-margin-expansion-and-cost-reduction/' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-11-03</td><td>-0.30</td><td></td><td>Share consolidation</td><td>-0.3 local feel              __   BABY.TO __    -> i:0.5<-                     **   ** 2025-11-06 **   <br><br>** 2025-11-06  Share consolidation ***<br>FEELING: total score -0.3 Reasoning: The primary event is a share consolidation. Share consolidations typically receive a negative score (-0.3) as they are often perceived as a sign of distress or a last-ditch effort to avoid delisting, even if the company states it's to improve trading liquidity. The news doesn't indicate any positive underlying financial improvements; it's a structural change. The other details (registered shareholder letters, warrant notifications, etc.) are procedural and have minimal financial impact. The focus on plant-based nutrition is promotional and backward-looking, receiving a very low score. --- <br> - The share consolidation, reducing shares from 374.1 million to approximately 37.4 million, aims to improve trading liquidity and potentially increase share price. Investors should understand the impact on their holdings and monitor the company's performance post-consolidation. <br><br>*** REZUMAT *** - Share consolidation approved: 1 share for every 10 pre-consolidation shares. - Trading on TSX to resume on consolidated basis Nov 6, 2025. - New CUSIP & ISIN: 290257500 & CA2902575000 respectively. - Shares reduced: From 374,114,284 to ~37,411,430 post-consolidation. - Registered shareholders will receive a letter of transmittal from Computershare. - Non-registered shareholders should contact their intermediary for processing. - Warrants issued Oct 20, 2021 & June 29, 2022 will be notified. - Company focuses on plant-based nutrition for infants, toddlers, and adults.   (gemma3:12b-it-q4_K_M on 2025-11-03 22:10:04)</td><td><a href='https://www.prnewswire.com/news-releases/else-nutrition-announces-share-consolidation-302603127.html' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-11-03</td><td>-0.35</td><td></td><td>stock split</td><td>-0.35 local feel              __   BABY.TO __    -> i:0.35<-                      <br><br>FEELING: total score -0.35 Here's a breakdown of the scoring: Share Consolidation: -0.1 (Share consolidations are generally viewed negatively as they can signal distress or an attempt to artificially inflate the stock price. While the stated aim is to improve market presence, the overall context is negative.) Declining Revenues and Negative Earnings: -0.3 (This is a significant negative factor, indicating financial distress and a lack of profitability. This outweighs the share consolidation.) TipRanks AI Analyst rating (Neutral): -0.05 (Analysts' ratings generally receive a low score, unless there is a clear consensus across all analysts.) Bearish Trend (Technical Analysis): -0.05 (Technical analysis is not a primary driver of fundamental value, but reinforces the negative sentiment.) Unfavorable Valuation Metrics: -0.05 (Reinforces the negative sentiment.) --- <br> - Else Nutrition is consolidating shares to improve market presence, but faces significant financial challenges including declining revenues and negative earnings. Investors should proceed with caution and closely monitor the company's turnaround efforts. <br><br>*** REZUMAT *** - Else Nutrition consolidates shares, reducing them from 374M to 37M. - Aim: Enhance market presence and streamline share structure. - TipRanks AI Analyst rates TSE:BABY as Neutral. - Overall stock score is 42, reflecting financial challenges. - Declining revenues and profitability are key negative factors. - Technical analysis indicates a bearish trend. - Valuation metrics are unfavorable due to negative earnings. - Market Cap: C$5.61M. - Average Trading Volume: 690,357. - Technical Sentiment Signal: Sell.   (gemma3:12b-it-q4_K_M on 2025-11-03 22:14:59)</td><td><a href='https://www.tipranks.com/news/company-announcements/else-nutrition-announces-strategic-share-consolidation' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-11-03</td><td>-0.30</td><td></td><td>Share consolidations</td><td>-0.3 local feel              __   BABY.TO __    -> i:0.5<-                     **   ** 2025-11-06 **   <br><br>** 2025-11-06  Share consolidations ***<br>FEELING: total score -0.3 Reasoning: The news primarily concerns a share consolidation (1-for-10). Share consolidations are generally viewed negatively as they often signal a company is trying to artificially inflate its stock price or avoid delisting, even though the underlying value doesn't change. This triggers a score of -0.3. The explanation that it "doesn't inherently change the company's value" is a mitigating factor, but the negative perception associated with consolidations remains. The rest of the information is purely logistical and doesn't carry significant financial implications. --- <br> - The share consolidation of 1-for-10 reduces the number of outstanding shares to approximately 37.41 million, effective November 6, 2025. While this doesn't inherently change the company's value, it can impact share price and liquidity. Investors should understand the implications for their holdings. <br><br>*** REZUMAT *** - Share Consolidation: 1-for-10 ratio approved by the board. - Effective Date: Trading will resume on Nov 6, 2025. - Symbol: Remains "BABY" on TSX. - Outstanding Shares: Reduced from 374.1M to ~37.41M. - CUSIP/ISIN: New numbers are 290257500 and CA2902575000. - Registered Shareholders: Will receive a transmittal letter from Computershare. - Non-Registered Shareholders: Should contact their intermediary for processing. - Warrants: Holders will receive notices regarding the consolidation effect. - Company Focus: Plant-based nutrition for infants, toddlers, children, and adults.   (gemma3:12b-it-q4_K_M on 2025-11-03 22:18:54)</td><td><a href='https://www.stocktitan.net/news/BABYF/else-nutrition-announces-share-2ew5goxhs9fh.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-10-28</td><td>0.30</td><td></td><td>Product launches</td><td>0.3 local feel              __   BABY.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: The news primarily discusses market growth projections for dairy alternatives in the infant market. This represents a positive outlook for companies operating in this space (0.3). The projected CAGR of 9.5% is a significant growth rate, suggesting increased demand and potential revenue growth for relevant companies. While the article mentions several competitors, it doesn's specifically highlight BABY.TO's position or actions. The FDA approval of new safety standards is a positive regulatory development (0.1). The article is largely descriptive and backward-looking (market size, past launches), so the overall impact is moderate. --- <br> - The dairy alternatives for infant market is poised for significant growth, projected at a 9.5% CAGR to reach USD 5,167 million by 2032. Driven by rising allergies, vegan trends, and nutritional innovation, investors should consider companies specializing in hypoallergenic and plant-based infant formulas, particularly those with established distribution networks and R&D capabilities. <br><br>*** REZUMAT *** - Market size: USD 2,500 million in 2024, projected to USD 5,167 million by 2032. - CAGR: 9.5% during 2025-2032. - Drivers: Rising milk allergies, veganism, plant-based nutrition preference. - Abbott Nutrition: Launched soy-based infant formula in October 2025. - FDA: Approved new safety standards for plant-based infant formulas in October 2025. - Danone: Introduced oat-based infant formula in October 2025. - Meiji Holdings: Launched rice-based infant formula in October 2025. - Key players: Abbott, Nestle, Danone, Reckitt Benckiser, Perrigo, Meiji, Morinaga, Else Nutrition, Sprout Organic, Little Spoon. - Segmentation: Soy-based, hypoallergenic, lactose-free formulas; Stage 1 & 2; Online & Offline channels; Organic & Conventional. - Geographic focus: North America, Europe, Asia-Pacific, South America, Middle East & Africa.   (gemma3:12b-it-q4_K_M on 2025-10-28 23:25:21)</td><td><a href='https://www.openpr.com/news/4242227/united-states-dairy-alternatives-for-infant-market-to-grow' target='_blank'>Link</a></td></tr></table></div></div>
    </div>
    </body>
    </html>
    